DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye
Executive Summary
- DiagnosTear Technologies Inc. obtained all required regulatory and ethics approvals to commence the TeaRx™ Red Eye clinical study, including French ANSM approval and a favourable opinion from the French Ethics Committee (CPPM Sud Méditerranée III).
- Contract Research Organization AlyaTec confirmed operational readiness; patient recruitment and sampling have begun.
- The study will evaluate total tear IgE as a biomarker for allergic conjunctivitis, advancing analytical validation and supporting the FDA submission pathway for TeaRx™ Red Eye.
Key Details
- Regulatory Approvals:
- ANSM (French National Agency for Medicines and Health Products Safety) approval secured.
-
Positive opinion from Comité de Protection des Personnes Sud Méditerranée III (French Ethics Committee).
-
Study Collaboration:
-
Ongoing partnership with AlyaTec, a CRO specializing in allergy and environmental disease research.
-
Operational Status:
-
AlyaTec reports operational readiness; patient recruitment and sample collection are now underway.
-
Study Design & Objectives:
- Enroll documented allergy patients for tear‑sample collection before and after controlled ocular allergy provocation.
-
Primary goal: analytically validate total tear IgE as a key biomarker for allergic conjunctivitis, strengthening the scientific and regulatory pathway for TeaRx™ Red Eye.
-
Strategic Impact:
- Successful validation will support FDA submission and accelerate commercialization roadmap for the multi‑biomarker diagnostic platform.
Notable Quotes
“Obtaining both regulatory and ethics approvals represents a significant milestone for our Red Eye program and reflects the strong scientific and clinical foundation of this study.” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.
“We are pleased to see the rapid operational progress at AlyaTec and the initiation of patient screening… these developments meaningfully advance our regulatory strategy and support our broader commercialization roadmap.” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.